COVID-19 and Cancer Patients: Understanding the Immune Response
Author Information
Author(s): Kosiorek Piotr, Mikołuć Bożena, Stróż Samuel, Hryniewicz Anna, Kazberuk Dorota E., Milewski Robert, Grzeszczuk Anna, Borkowska Magdalena J., Stasiak‐Barmuta Anna
Primary Institution: Maria Sklodowska‐Curie Bialystok Oncology Centre, Białystok, Poland
Hypothesis
What is the impact of the cancer process on the humoral response in oncological patients vaccinated against SARS-CoV-2 infection and in patients after COVID-19?
Conclusion
The study found that cancer patients exhibited a stronger humoral response to SARS-CoV-2 infection compared to those who were vaccinated and treated for cancer.
Supporting Evidence
- Vaccination is crucial for cancer patients to enhance their immune response against COVID-19.
- Patients with breast, lung, colon, kidney, and testicular cancer showed significant humoral responses.
- Unvaccinated cancer patients exhibited a stronger immune response to SARS-CoV-2.
- Chemotherapy and radiotherapy can influence antibody levels in cancer patients.
- Age and gender distribution were significant factors in the immune response observed.
Takeaway
This study shows that cancer patients can have a strong immune response to COVID-19, especially if they haven't been vaccinated or treated for cancer.
Methodology
The study involved a retrospective analysis of medical records from 1668 patients over 2 years, measuring SARS-CoV-2 IgG and IgM antibody levels.
Potential Biases
The groups were not randomized, which may introduce selection bias.
Limitations
The study did not maintain a protocol for reasons for antibody referrals and did not include inflammation or comorbidities in patient data.
Participant Demographics
The study included 1718 females and 823 males, with a significant portion being over 60 years old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website